Response from Dr. Sherer

When faced with a single value of CD4 cell count and viral load that are very inconsistent with past results, as in your case, the reasonable response is to repeat the tests right away. I certainly suggest that you do so.
It would also be appropriate to obtain a genotype resistance test at the same time, so that you can understand whether resistance to one or more of these drugs has occured. Drug resistance might explain why you have developed rapid virologic failure (if these test results are confirmed).
You did not mention whether your doctor obtained a resistance test in September before you were started on the first regimen. It is possible that you were infected with a virus that contained resistance mutations to one or more of the meds in your current regimen.
At the same time, these test results would prompt me to look for any explanations for the change in your status, i.e. review your adherence (which you note has been near perfect), any other illnesses, infections, or vaccinations, other medications that might interact with your HIV meds, etc.
Finally, and unfortunately, while the results with ART in general, and with your current regimen specifically, are excellent, they are not perfect. In clinical trials of regimens similar to stavudine, 3TC, and efavirenz, 3/4 of patients were well controlled for 1-2 years. Among the 1/4 who experienced virologic failure were individuals who, like you, 'did everything right', i.e. took all meds as prescribed, and lived healthy lifestyles.
Finally, I encourage you not to lose hope, or to feel that this is somehow your fault. Nor is this the last option for durable successful ART for you - it is still feasible that you and your doctor can identify the issues in these current lab tests and choose another regimen that can be fully suppressive for a prolonger period of time.
Your doctor knows the exact circumstances of your history and current treatment far better than I, so I suggest that you talk to him or her about this situation, your questions, and this response.
|